|
|||||
|
|
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. |
|
| Authors: | Z Culig J Hoffmann M Erdel I E Eder A Hobisch A Hittmair G Bartsch G Utermann M R Schneider K Parczyk H Klocker |
| Affiliation: | Department of Urology, University of Innsbruck, Austria. |
| Abstract: | |
| Keywords: | prostate cancer androgen ablation LNCaP cells androgen receptor bicalutamide tumour progression |